Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

Your spleen might not get the glory of organs like your heart or brain, but its contributions to your immune system are ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to Fate's FT819 ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...